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ABSTRACT   
Epithelial changes may contribute to the development of symptoms in individuals
without as well as with airway hyperresponsiveness. In smokers the occurrence of
squamous metaplasia leads to impaired normal epithelial function causing symptoms
like phlegm and cough. We have evaluated expression of different types of relevant
cytokeratins and integrins involved in epithelial adhesion to extracellular matrix.
Immunohistological studies were performed using bronchial biopsies of subjects with
and without chronic respiratory symptoms (Sy+ and Sy-) in combination with
presence or absence of airways hyperresponsiveness (AHR+ and AHR-). Bronchial
biopsies were obtained from 14 Sy+AHR+ subjects, 12 Sy+AHR- subjects, 12 Sy-
AHR+ subjects and 19 Sy-AHR- subjects. Cytokeratin 8 and VLA2 were present in
almost all cells in all subjects. Cytokeratin 7 (CK7) stained mainly ciliated cells, and
less clear in basal cells or goblet cells. Areas with squamous metaplasia showed
weak or negative CK7 staining. Cytokeratin 10 was absent in all subjects. Cytokeratin
18 was variably present, mainly in non-basal epithelial cells. VLA3 was seen in
epithelium of all subjects and VLA6 in 18 subjects in a variable presence and
intensity. Presence of VLA3 and VLA6 in the basal membrane was variable, possibly
related to changes in the overlying epithelium. Expression of cytokeratins and
integrins in the bronchial epithelium showed no significant differences between the
four groups under study. The presence of chronic respiratory symptoms during the
previous three years and not necessarily at the time of the study, and the
heterogeneity of subject characteristics, such as atopy and smoking habits, might
imply that more study subjects are needed to reach sufficient power. Further
evaluation of extended study groups should reveal whether early epithelial changes
(preceding morphological changes) are related to smoking and to the presence or
development of respiratory symptoms. The finding of a subtle decrease in presence
of CK7 and gain of VLA6 expression in bronchial epithelium seem worth further
exploration, in particular in relation to smoking habits.
INTRODUCTION
Cross-sectional population studies investigating the relationship between airway
hyperresponsiveness (AHR) and respiratory symptoms have shown that the presence
of AHR is associated with respiratory symptoms, such as wheeze, breathlessness,
and chest tightness (1-4). Although there is a strong association, not all subjects with
AHR have respiratory symptoms and not all subjects with respiratory symptoms have
AHR (4). 
Epithelial changes may contribute to the development or presence of respiratory
symptoms in individuals, irrespective of presence of airways hyperresponsiveness
(5,6). Smoking induces hyperplasia of goblet cells and mucus glands, which results
in mucus overproduction. In the long run, squamous metaplasia occurs in susceptible
smokers, which further hinders the adequate transport of mucus to the pharyngeal
area (5,6). This leads to development of symptoms like phlegm and cough. Further,
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mediators produced by inflammatory cells (e.g., in asthma) may damage epithelial
attachments to the basement membrane and to each other, giving further rise to
inadequate mucus transport and development of symptoms (7). The epithelial
changes described above are accompanied by differences in presence of
differentiation-specific types of the intermediate filament cytokeratin (8,9) and likely
by changes in functional surface molecules like adhesion molecules (10,11). Part of
these shifts in expression may precede clear morphological changes like metaplasia,
or actual detachment. Such changes may already have impact on the function of
epithelial cells, thereby possibly giving rise to the development of early symptoms. 
In this study bronchial biopsies were obtained from a sample of 57 subjects from a
general adult population to determine whether differences in characteristics of
epithelial cells of the airways are related to the presence of respiratory symptoms
and/or airway hyperresponsiveness. Immunohistological studies were performed to
evaluate expression of relevant cytokeratins (CK) types 7, 8, 10 and 18, and 1-
integrins involved in epithelial adhesion to extracellular matrix:  VLA2 ( 2-chain),
VLA3 ( 3-chain) and VLA6 ( 6-chain). We have compared this expression in
bronchial biopsies of subjects with and without symptoms (Sy+ and Sy-) in




In 1995 and 1996, we examined 57 subjects of whom complete information was
available of the final surveys of the longitudinal Vlagtwedde-Vlaardingen Study at
Vlagtwedde in 1989 or 1985. The Vlagtwedde-Vlaardingen Study is a longitudinal
population study that started in 1965 and was originally designed to determine risk
factors for the natural history of chronic obstructive lung diseases (1,12). The initial
cohort in Vlagtwedde consisted of a random sample of 450 subjects 40 to 44 years of
age and of 1,793 subjects 15 to 39 years of age with baseline measurements in 1965
and 1967, respectively. After the baseline surveys the cohorts participated in follow-
up surveys approximately every 3 years. All surveys were carried out during the
month of October.
The selection of subjects and an overview of measurements that were performed are
described in Chapter 6. Subjects were considered symptomatic if they reported one
or more of the following chronic respiratory symptoms: cough or phlegm production
on most days or nights for as much as 3 consecutive months each year during winter
(referred to as chronic cough/chronic phlegm), a period of at least 3 weeks in the
previous 3 years with (increased) cough and phlegm (bronchitis episodes), shortness
of breath when walking with other persons of the same age on level ground (dyspnea
$ Grade 3), a wheezing or whistling sound in the chest on most days or nights
(persistent wheeze), or attacks of shortness of breath in the previous 3 years (asthma
attacks). The presence of AHR was defined as PC20 #8 mg/ml histamine. Bronchial
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biopsies were obtained from 14 Sy+AHR+ subjects, 12 Sy+AHR- subjects, 12 Sy-
AHR+ subjects and 19 Sy-AHR- subjects. 











CK8 na - 52.8 na non-squamous
epithelium
CK10 na - 56.5 na epidermal squamous
epithelium
CK18 na - 45 na non-squamous
epithelium*
2ß1 CD49b/CD29 VLA2 170130 Coll(I-III,IV), Ln Pl, F, EN, Ep,
activated T-ly
3ß1 CD49c/CD29 VLA3 130/25,130 Coll(I), Ln, Fn, Epil Ep, F, BM, B-ly
6ß1 CD49f/CD29 VLA6 120/30,130 Ln, Inv BM, Pl, T-ly, Ep, Th,
M
CD=cluster of differentiation; Coll=collagen; Epil=Epiligrin; Fn=fibronectin; Inv=invasin; Ln=laminin; MW=
molecular weight; na= not applicable; VLA=very late activation antigen
Distribution: BM=basement membrane associated; EN=endothelial cells; Ep=epithelial cells; F=fibroblasts;
Ly=lymphocytes; M=monocytes/macrophages; Pl=platelets; Th=thymocytes
* expression of CK18 similar but generally less prominent than CK7
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Biopsy processing and analysis
Bronchoscopy was performed using an Olympus flexible fiberoptic bronchoscope
(Olympus Optical, Tokyo, Japan). Lidocaine (2% and 4%) was used for local
anaesthesia. Four to six biopsies were taken from the subcarinae of the left or right
lower lobe using a fenestrated forceps (FB-21C, Olympus, Tokyo, Japan). Biopsies
were immersed in Tissue Tek ®  mounting medium, snap frozen in liquid isopentane
and stored at -80EC until use. Serial sections were cut at 4µ. Two sections at an
interval of 100 µm were stained for each antigen to be determined. 
In order to evaluate the bronchial architecture of the sections, we stained each 50th
section with Mayer's hematoxylin and eosin (HE) to verify for the quality of the biopsy
mainly focussed on presence of sufficient surface epithelium to be evaluated.
When none of the HE stained sections satisfied the criteria, the next biopsy was cut
till a morphologically adequate series of 15 sections was available. The sections
were stored at -20EC.
A three step immunoperoxidase staining using the streptavidin biotin method was
used. Biopsies were incubated with the specific monoclonal antibodies followed by a
detection step using goat anti-mouse immunoglobulin antiserum coupled to biotin
and subsequently streptavidin conjugated to peroxidase. Each incubation step was
followed by a 5 min. washing in phosphate buffered saline (pH 7.2). 3-Amino-9-Ethyl
Carbazole (AEC) was used as a substrate giving a reddish brown reaction
production. The following monoclonal antibodies were used (Table 1): anti-
cytokeratins types 7, 8, 10 and 18 (all from Eurodiagnostics, Apeldoorn, NL), mAb to
1-integrin VLA2 ( 2-chain), and VLA6 ( 6-chain) both from CLB (Central Laboratory
Bloodtransfusion service, Amsterdam, The Netherlands) and VLA3 ( 3-chain) from
Telios Pharmaceuticals.
Metaplasia was determined using HE stained slides. Often partial metaplastic
changes were observed. The immunohistochemical results for the epithelium were
expressed as absent (score 0) or present (score 1).  Since there was only little
variation in staining intensity of the epithelial cells, the degree in staining intensity
was not scored. The staining of basal epithelial cells and non-basal epithelium was
determined separately. Part of the biopsies showed some epithelial shedding, likely
due to mechanical damage. In all biopsies sufficient epithelium was available for
evaluation. In areas with epithelial shedding the remaining basal cells showed, in
general, an identical pattern as the basal cells in intact areas. Staining of the
basement membrane is given semiquantitatively as absent (score 0), weak (score 1)
or strong (score 2). Two independent observers performed all evaluations.
Data analyses
Chi-square tests and Fisher’s exact tests were performed to determine differences
between the groups for categorical variables. Differences between the groups for





The most commonly reported symptoms as also described in chapter 6 were
bronchitis episodes, chronic cough, and chronic phlegm (Table 2). The majority of
subjects with bronchitis episodes (12 out of 17) reported having had such episodes
more than once, and 9 of them also experienced at least one of the other respiratory
symptoms. Chronic cough and/or phlegm were reported by 13 subjects of whom 2
also reported dyspnea and/or persistent wheeze.
Table 2. Respiratory symptoms by airway hyperresponsiveness (AHR: 
PC20 # 8 mg/ml)
AHR- AHR+ Total group
n  (%) n  (%) n  (%)
Chronic cough 5 (41.7) 5 (35.7) 10 (38.5)
Chronic phlegm 4 (33.3) 6 (42.9) 10 (38.5)
Bronchitis episodes 5 (41.7) 12 (85.7) 17 (65.4)
Dyspnea $Grade 3 1 ( 8.3) 4 (28.6) 5 (19.2)
Persistent wheeze 0 --- 2 (14.3) 2 ( 7.7)
Asthma attacks 2 (16.7) 1 ( 7.1) 3 (11.5)
One or more symptoms 12 (100) 14 (100) 26 (100)
The characteristics of the study population are described in Table 3. In short, mean
age of this population is 56 years, 25% are current smokers, and 37% had one or
more positive skin tests. Symptomatic hyperresponsive subjects (Sy+AHR+) were
significantly more frequently current smokers and had a significantly lower lung
function (FEV1 %predicted and FEV1 %VC) than Sy-AHR- subjects. Airway
hyperresponsiveness was more severe in Sy+AHR+ subjects than in Sy-AHR+
subjects.
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Table 3.  Characteristics of the Vlagtwedde population of 1995/1996
Respiratory symptoms and AHR
Characteristics Sy-AHR- Sy-AHR+ Sy+AHR- Sy+AHR+ Total group
n, (% men)  19 (63)  12 (42)  12 (58)  14 (50)  57 (54)
Age, yr
 56 ± 7  54 ± 5  55 ± 7  59 ± 10  56 ± 8
Smoking habits:
  Non smoker  7 (37)  3 (25)  2 (17)  1 (7) 13 (23)
  Ex-smoker 10 (53)  7 (58)  7 (58)  6 (43) 30 (53)
  Current smoker  2 (10)  2 (17)  3 (25) 
 7 (50) * 14 (25)
FEV1 %predicted 124.8 ± 19.3 113.4 ± 15.9 118.0 ± 16.4 102.2 ± 20.7 *¶ 115.4 ± 19.9
FEV1/VC, % 75.8 ± 3.8 72.2 ± 6.5 74.2 ± 6.8 66.5 ± 10.1 * 72.4 ± 7.7
PC20 histamine 4.63 ± 2.2 1.67 ± 2.5 §
Reversible airways 
obstruction 1)
0 (0) 5 (42) 1 (8) 10 (71) ¶ 16 (28)
$1 positive skin test 2) 7 (37) 5 (42) 5 (42) 4 (29) 21 (37)
* p<0.05 compared with Sy-AHR-, § p<0.05 compared with Sy-AHR+, ¶ p<0.05 compared with Sy+AHR-.
Smoking habits, reversibility and skin test positivity: n (%). Other parameter are expressed as mean ± standard
deviation.
1)
 $ 9% predicted after 200 µg salbutamol; 2) 12 allergens tested: mixed grass pollen, mixed tree pollen, mixed
weeds, house dust mites, mixed storage mites, animal danders.
Morphology and Immunohistochemistry
The results are summarized in Table 4. Squamous metaplasia was observed in 10
out of 57 subjects. Cytokeratin 7 (CK7) stained mainly ciliated cells, and less clear in
basal cells or goblet cells. Areas with squamous metaplasia showed weak or
negative CK7 staining. Cytokeratin 8 and VLA2 were present in almost all epithelial
cells (including squamous metaplasia) in all subjects. Cytokeratin 18 was mainly
present in non-basal epithelial cells in a variable presence and intensity. Cytokeratin
10 was absent in all subjects, even in areas with metaplastic epithelium. VLA3 was
seen in all subjects in epithelial cells in a variable presence and intensity, and its
expression did not correlate to the presence of metaplasia (Chi-square test: p=0.48).
VLA6 stained epithelial cells in 18 out of 55 subjects with variable, generally weak,
expression. This included 9 out of 10 subjects who had metaplastic epithelial
changes. VLA6 expression in epithelial cells did not correlate to CK7 expression in
basal epithelial cells (Chi-square test: p=0.56) and in ciliated
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epithelial cells (Chi-square test: p=0.44). VLA2, VLA3 and VLA6 expression was 
not different between basal and non-basal epithelial cells. Both VLA3 and VLA6
stained the basal membrane in all subjects with variable intensity.
Table 4. Results of immunohistochemical characterization (% positive)1
Sy-AHR- Sy-AHR+ Sy+AHR- Sy+AHR+
Metaplasia, n/total n (%) 3/19 (15.8) 1/12 (8.3) 2/12 (16.7) 4/14 (28.6)
CK7 basal epithelium 9/19 (47.4) 7/11 (63.6) 6/12 (50.0) 10/14 (71.4)
CK7 non-basal epithelium 13/19 (68.4) 10/11 (90.9) 7/12 (58.3) 11/14 (78.6)
CK8 epithelium (all) 19/19 (100) 11/11 (100) 12/12 (100) 14/14 (100)
CK10 epithelium (all) 0 0 0 0
CK18 basal epithelium 0 0 0 0
CK18 non-basal epithelium 10/19 (52.6) 8/11 (72.7) 8/12 (66.7) 11/14 (78.6)
VLA2 epithelium 19/19 (100) 11/11 (100) 12/12 (100) 14/14 (100)
VLA3 epithelium 10/19 (52.6) 7/11 (63.6) 7/12 (58.3) 8/14 (57.1)
VLA6 epithelium 4/19 (21.1) 3/11 (27.3) 5/12 (41.7) 6/14 (42.9)
VLA3 basal membrane weak 3/19 (15.8) 2/12 (16.7) 0 4/14 (28.6)
VLA3  basal membrane strong 11/19 (57.9) 7/12 (58.3) 7/12 (58.3) 6/14 (42.9)
VLA6 basal membrane weak 4/19 (21.1) 0 1/11 (9.1) 3/14 (21.4)
VLA6 basal membrane strong 9/19 (47.4) 9/11 (81.8) 8/11 (72.7) 9/14 (64.3)
1
 All results are expressed as the fraction of subjects within each group, with metaplasia or positive stainings.
The percentages are described between brackets.
















































































Figure 1. Cytokeratin (CK) 7 expression in ciliated cells by smoking habits
No differences were found between the four groups with respect to epithelial
expression of cytokeratins and 1-integrins. Some differences were found in relation
to smoking habits. CK7 expression in ciliated cells was observed less frequently in
ex-smokers (58.6%) than never smokers (92.3%) and current smokers (85.7%)
(p=0.04) (Figure 1). VLA6 expression in epithelium was found in more current
smokers (50%) than in ex-smokers (34.5%) or never smokers (7.7%) (p=0.05)
(Figure 2). Presence of VLA3 in the basal membrane was more frequently observed
in current-smokers than ex-smokers  (p=0.01) (Figure 3).
      
            













































Figure 3. VLA3 expression in the basal membrane by smoking habits
DISCUSSION
In this study on a sample of a general elderly population, we investigated whether
epithelial differences in the airways are related to the presence of symptoms and/or
airway hyperresponsiveness. Our results show that cytokeratin 8 and VLA2 were
present in almost all cells in all subjects. Cytokeratin 10, in general related to highly
differentiated squamous epithelium, was absent in all subjects and cytokeratin 7 and
18, and VLA3 showed variable expression in epithelial cells. Although our first
impression was that the variability of the latter might be related to the presence of
squamous metaplasia, no clear correlation could be demonstrated. Presence of
VLA2 and VLA3 is consistent with other reports (11,13). Further, presence of VLA3
and VLA6 in the basal membrane was variable, possibly related to changes in the
overlying epithelium.
The lack of CK10 indicates that the metaplastic squamous epithelium is not highly
differentiated (8). The relative absence of CK7 in areas with squamous cell
metaplasia, together with the variable expression found in some subjects in the basal
cell area suggest that it may be possible that these areas represent an early phase of
developing (so called “immature”) metaplasia (14,15). This might imply an
impairment of differentiated bronchial epithelial cell function (14). Nevertheless, we
were not able to establish a relationship between diminished CK7 expression and
presence of symptoms. Since metaplasia is known to remain for considerable time
after stopping smoking (5), it is tempting to attribute the finding of fewer ex-smokers
than never smokers with CK7 expression to the above suggestion of development of
Airway epithelium, respiratory symptoms, and AHR
111
immature metaplasia. The absence of a clear relationship of smoking status with
morphologically observed metaplasia and the not clearly diminished number of
subjects with CK7 epithelial expression among current smokers preclude any
conclusions. Moreover, this indicates that our studies should be extended in number
of subjects and likely also with additional parameters that enable better
characterization of epithelial differentiation, including better morphology. One
possibility to obtain the latter goal is to use paraffin embedded biopsies, which allow
staining for different cytokeratins in combination with better morphology and the
possibility to use mucin stains for determination of mucinous bronchial epithelial
cells.
The trend for an association of epithelial VLA6 expression with current smoking as
opposed to non- or ex smoking, is another characteristic that is worth further survey.
As this was observed in 9 out of 10 cases with squamous metaplasia (together with 9
cases in which no clear morphologic metaplasia was observed), this may also be of
use in future attempts to establish immature metaplasia. Epithelial VLA6 expression
was not found to be associated with diminished epithelial CK7 expression.
The lack of discriminating characteristics in the bronchial epithelium may be
attributed to the same factors that were described in chapter 6A. Subjects were not
selected from a patient population and symptomatic subjects were defined as having
chronic respiratory symptoms during the previous three years. Thus, not all
symptoms may actually have been present at the time of the survey. However,
chronic cough and phlegm present during the previous three years were, in general,
also present at the time of the biopsy procedure. Maybe even more than in relation to
inflammation in the airway wall, epithelial changes can be expected to have a causal
relationship to the presence of symptoms. Also, again similar to the evaluation of
inflammation, the heterogeneity of our study population with regard to characteristics
such as atopy and smoking history may be responsible for the variability in epithelial
characteristics, making it difficult to observe unadjusted differences between the
groups. Last, the number of subjects in the groups may have been too low, when
confronted with the above-described heterogeneity as present in a study population
like ours. Further evaluation using extended numbers of subjects should reveal
whether early epithelial changes (preceding morphological changes) are related to
the presence or development of respiratory symptoms.
Altogether, despite the limitations described above, the finding of in particular a
subtle decrease in presence of CK7 and gain of VLA6 expression in bronchial
epithelium seem worth further exploration in future studies. CK7 and VLA6
expression may indicate changes in normal bronchial epithelial function in relation to
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